Results 1 to 10 of about 407,619 (292)

Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario

Current Oncology, 2021
The COVID-19 pandemic has a significant impact on cancer patients and the delivery of cancer care. To allow clinicians to adapt treatment plans for patients, Ontario Health (Cancer Care Ontario) issued a series of interim funding measures for the ...
Rohini D. Naipaul, Rebecca E. Mercer, Kelvin K. W. Chan, Lyndee Yeung, Leta Forbes, Scott Gavura   +5 more
doaj   +1 more source

Use of [177Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study

EJC Supplements, 2021
Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs).
Matthew Glover, Martyn Caplin, Oscar R. Leeuwenkamp, Louise Longworth   +3 more
doaj   +1 more source

Barriers and Facilitators in Pricing and Funding Policies of European Countries That Impact the Use of Point-of-Care Diagnostics for Acute Respiratory Tract Infections in Outpatient Practices

Diagnostics, 2023
Antimicrobial resistance is a major global health threat, which is increased by the irrational use of antibiotics, for example, in the treatment of respiratory tract infections in community care.
Caroline Steigenberger, Friederike Windisch, Sabine Vogler   +2 more
doaj   +1 more source

Public spending on orphan medicines: a review of the literature

Journal of Pharmaceutical Policy and Practice, 2020
Background and objective Little is known about how much public payers spend on orphan medicines. This study aimed at identifying information on orphan medicine expenditure incurred by public payers that was published in literature globally and at ...
Margit Gombocz, Sabine Vogler
doaj   +1 more source

Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice

Biotechnology & Biotechnological Equipment, 2023
Randomized controlled trials (RCTs) are typically conducted in highly selected patient populations to ideally demonstrate unconfounded clinical efficacy of a drug.
Manoela Manova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Margit Hemetsberger, Arkadi Sharkov, Boryana Zidarova, Dimitrina Apostolova, Maria Vasileva, Silvia Terezova, Mila Vlaskovska, Alexandra Savova   +12 more
doaj   +1 more source

Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06) [PDF]

The Korean Journal of Internal Medicine, 2023
Background/Aims Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease.
Jung Sun Kim, Tae Min Kim, Myoung Joo Kang, Sung Ae Koh, Hyunkyung Park, Seung-Hyun Nam, Jae Joon Han, Gyeong-Won Lee, Young Jin Yuh, Hee Jeong Lee, Jung Hye Choi   +10 more
doaj   +1 more source

Geographic and Age-Based Variations in Medicare Reimbursement Among ASSH Members. [PDF]

, 2016
Background: The purpose of this study was to investigate how American Society for Surgery of the Hand (ASSH) members\u27 Medicare reimbursement depends on their geographical location and number of years in practice. Methods: Demographic data for surgeons
Gaspar, Michael P., Honik, Grace B., Jacoby, Sidney M., Kane, Patrick M., Osterman, A. Lee, Shin, Eon K.   +5 more
core   +2 more sources

Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice [PDF]

Pharmacia
Malignant melanoma is among the leading forms of cancer on a global scale, accounting for 1 in 5 skin cancers. Over the past decades, the treatment of melanoma has significantly improved following the development of therapies such as MAPK molecular ...
Alexandra Savova, Boryana Ivanova, Gergana Shalamanova, Iva Gavrilova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Martina Nacheva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Manoela Manova   +14 more
doaj   +3 more sources

Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation

Cost Effectiveness and Resource Allocation, 2020
Background Several governments apply the policy of external price referencing (EPR), which considers the prices of a medicine in one or more other countries for the purpose of setting the price in the own country.
Sabine Vogler, Peter Schneider, Lena Lepuschütz   +2 more
doaj   +1 more source

Assessing, Pricing and Funding Point-of-Care Diagnostic Tests for Community-Acquired Acute Respiratory Tract Infections–Overview of Policies Applied in 17 European Countries

Antibiotics, 2022
Point-of-care diagnostic tests for community-acquired acute respiratory tract infections (CA-ARTI) can support doctors by improving antibiotic prescribing.
Sabine Vogler, Friederike Windisch
doaj   +1 more source